Acyclovir exposure and birth defects: An important advance, but more are needed

JAMA

Volumn 304, Issue 8, 2010, Pages 905-906

  Mills, James L ^a   Carter, Tonia C ^a  

^a EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH AND HUMAN DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; FAMCICLOVIR; VALACICLOVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; BIRTH DEFECT; COHORT ANALYSIS; DISEASE ASSOCIATION; DISEASE REGISTRY; DRUG SAFETY; EDITORIAL; ELECTRONIC MEDICAL RECORD; FIRST TRIMESTER PREGNANCY; HEALTH CARE SYSTEM; HERPES SIMPLEX; HERPES SIMPLEX VIRUS; HUMAN; INFANT; LIVE BIRTH; ORGANOGENESIS; PREGNANT WOMAN; PRENATAL DRUG EXPOSURE; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; TERATOGENICITY; UNITED STATES; CONGENITAL MALFORMATION; DENMARK; FEMALE; INFORMATION PROCESSING; NOTE; PREGNANCY; REGISTER; SAMPLE SIZE; STATISTICS;

ABNORMALITIES, DRUG-INDUCED; ACYCLOVIR; ANTIVIRAL AGENTS; COHORT STUDIES; DATA COLLECTION; DENMARK; FEMALE; HERPES SIMPLEX; HUMANS; PREGNANCY; PREGNANCY TRIMESTER, FIRST; REGISTRIES; SAMPLE SIZE; UNITED STATES;

EID: 77955960612     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.1214     Document Type: Editorial

References (10)

1. Xu F, Markowitz LE, Gottlieb SL, Berman SM. Seroprevalence of herpes simplex virus types 1 and 2 in pregnant women in the United States. Am J Obstet Gynecol. 2007;196(1):43.e1-43.e6. (Pubitemid 46107368)
2. Brown ZA, Selke S, Zeh J, et al. The acquisition of herpes simplex virus during pregnancy. N Engl J Med. 1997;337(8):509-515. (Pubitemid 27352016)
3. Wilton LV, Pearce GL,Martin RM,Mackay FJ, Mann RD. The outcomes of pregnancy in women exposed to newly marketed drugs in general practice in England. Br J Obstet Gynaecol. 1998;105(8):882-889.
4. Reiff-Eldridge R, Heffner CR, Ephross SA, Tennis PS, White AD, Andrews EB. Monitoring pregnancy outcomes after prenatal drug exposure through prospective pregnancy registries: a pharmaceutical company commitment. Am J Obstet Gynecol. 2000;182(1 pt 1):159-163. (Pubitemid 30074385)
5. Ratanajamit C, Vinther Skriver M, Jepsen P, Chongsuvivatwong V, Olsen J, Sørensen HT. Adverse pregnancy outcome in women exposed to acyclovir during pregnancy: a population-based observational study. Scand J Infect Dis. 2003;35(4):255-259. (Pubitemid 36806035)
6. Stone KM, Reiff-Eldridge R, White AD, et al. Pregnancy outcomes following systemic prenatal acyclovir exposure: conclusions from the international acyclovir pregnancy registry, 1984-1999. Birth Defects Res A Clin Mol Teratol. 2004;70(4):201-207.
7. Pasternak B, Hviid A. Use of acyclovir, valacyclovir, and famciclovir in the first trimester of pregnancy and the risk of birth defects. JAMA. 2010;304(8):859-866.
8. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353(5):487-497.
9. Health Information Technology for Economic and Clinical Health Act of 2009, 42 USC §201 (2009).
10. Foundation for the National Institutes of Health. Observational medical outcomes partnership. http://omop.fnih.org/. Accessed July 23, 2010.